| pubmed-article:9626220 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C1518418 | lld:lifeskim |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C0555198 | lld:lifeskim |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:9626220 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9626220 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9626220 | pubmed:dateCreated | 1998-7-1 | lld:pubmed |
| pubmed-article:9626220 | pubmed:abstractText | To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. | lld:pubmed |
| pubmed-article:9626220 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9626220 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9626220 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9626220 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9626220 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9626220 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9626220 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9626220 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9626220 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:GilbertMM | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:SpenceA MAM | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:RobinsH IHI | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:ChangS MSM | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:KuhnJ GJG | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:PollackII | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:RankinCC | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:BergerM SMS | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:PradosM DMD | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:ScholdS CSCJr | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:NIZZAFF | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:MalekEE | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:FultonDD | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:RizzoJJ | lld:pubmed |
| pubmed-article:9626220 | pubmed:author | pubmed-author:BozikM EME | lld:pubmed |
| pubmed-article:9626220 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9626220 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:9626220 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9626220 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9626220 | pubmed:pagination | 2188-94 | lld:pubmed |
| pubmed-article:9626220 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:meshHeading | pubmed-meshheading:9626220-... | lld:pubmed |
| pubmed-article:9626220 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9626220 | pubmed:articleTitle | Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. | lld:pubmed |
| pubmed-article:9626220 | pubmed:affiliation | Department of Neurosurgery, University of California, San Francisco, USA. changs@neuro.ucsf.edu | lld:pubmed |
| pubmed-article:9626220 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9626220 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9626220 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9626220 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9626220 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9626220 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9626220 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9626220 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9626220 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9626220 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9626220 | lld:pubmed |
